UCB's Global Corporate Website

This section is intended for media and financial analysts

Transparency notifications

Brussels (Belgium), 7 December 2016 – 20:00 (CEST) – regulated information

1. Summary of the notifications

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 2 transparency notifications from BlackRock, Inc. (having its registered offices at 55 East 52nd Street, New York, NY, 10055, U.S.A.), dated 2 and 6 December 2016 respectively.

In the first notification, BlackRock, Inc. informed that, following an acquisition of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV had increased and had crossed the 3% threshold on 1 December 2016. In the second notification, BlackRock, Inc. notified that it crossed downward the 3% minimum threshold again, following a disposal of UCB shares with voting rights by its affiliates on 2 December 2016.

On 1 December 2016, BlackRock, Inc. (taking into account the holding of its affiliates) owned 5 847 777 UCB shares with voting rights (versus 5 749 621 shares in its previous notification dated 14 November 2016), representing 3.01% of the total number of shares issued by the company (194 505 658) (versus 2.96% in the notification of 14 November 2016).

On 2 December 2016, BlackRock, Inc. (taking into account the holding of its affiliates) announced that it owned 5 820 942 UCB shares with voting rights, representing 2.99% of the total number of shares issued by the company.

2. Content of the notifications

The transparency notification dated 2 December 2016 included the following information:

  • Date on which the threshold is crossed: 1 December 2016.
  • Threshold crossed (in %): 3%.
  • Notified details:

 

 

  • Additional information: The disclosure obligation arose due to voting rights for BlackRock, Inc. going above 3% in heading 10) A).

The transparency notification dated 6 December 2016 included the following information:

  • Date on which the threshold is crossed: 2 December 2016.
  • Threshold crossed (in %): 3%.
  • Notified details:

 


 

  • Additional information: The disclosure obligation arose due to voting rights for BlackRock, Inc. going below 3% in heading 10) A).

The information mentioned hereafter was identical in both notifications:

  • Reason for the notification: Acquisition or disposal of voting securities or voting rights.
  • Notification by: A parent undertaking or a controlling person.
  • Persons subject to the notification requirement:

 

  • Denominator: 194 505 658.
  • Chain of controlled undertakings through which the holding is effectively held:

Please see the full chain of control in a PDF which is sent separately to this notification.

3. Further information


This press release and the detailed transparency notifications (including the chain of control) are available on UCB SA/NV’s website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be included in the corporate governance charter of UCB SA/NV, which is available on its website via the following link.

Investor Relations

Antje Witte         
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,
 Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 3.9 billion in 2015. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

 

 

Asset Download

Stay up-to-date on the latest news and information from UCB

Subscribe